Robert A Mccutcheon

List of Publications by Year
in descending order

71 papers	5,767 citations	201674 27 h-index	102487 66 g-index
82 all docs	82 docs citations	82 times ranked	6470 citing authors

#	Article	IF	Citations
1	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. American Journal of Psychiatry, 2017, 174, 216-229.	7.2	685
2	Glutamate and dopamine in schizophrenia: An update for the 21st century. Journal of Psychopharmacology, 2015, 29, 97-115.	4.0	596
3	Schizophreniaâ€"An Overview. JAMA Psychiatry, 2020, 77, 201.	11.0	569
4	Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry,the, 2020, 7, 64-77.	7.4	506
5	Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms. Trends in Neurosciences, 2019, 42, 205-220.	8.6	441
6	The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia. Biological Psychiatry, 2017, 81, 9-20.	1.3	416
7	Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry, 2020, 19, 15-33.	10.4	301
8	Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. Translational Psychiatry, 2017, 7, e1024-e1024.	4.8	193
9	Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis. Schizophrenia Bulletin, 2018, 44, 1301-1311.	4.3	187
10	Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology, 2020, 172, 107704.	4.1	180
11	Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry,the, 2020, 7, 344-353.	7.4	147
12	Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. Molecular Psychiatry, 2019, 24, 776-794.	7.9	124
13	A Meta-analysis of Immune Parameters, Variability, and Assessment of Modal Distribution in Psychosis and Test of the Immune Subgroup Hypothesis. Schizophrenia Bulletin, 2019, 45, 1120-1133.	4.3	113
14	Brain-imaging studies of treatment-resistant schizophrenia: a systematic review. Lancet Psychiatry,the, 2016, 3, 451-463.	7.4	106
15	Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia. JAMA Network Open, 2020, 3, e204693.	5.9	103
16	The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study. Lancet Psychiatry,the, 2018, 5, 816-823.	7.4	89
17	Sleep and Circadian Rhythm Disturbance in Remitted Schizophrenia and Bipolar Disorder: A Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2020, 46, 1126-1143.	4.3	83
18	Antipsychotic plasma levels in the assessment of poor treatment response inÂschizophrenia. Acta Psychiatrica Scandinavica, 2018, 137, 39-46.	4.5	76

#	Article	IF	Citations
19	Mesolimbic Dopamine Function Is Related to Salience Network Connectivity: An Integrative Positron Emission Tomography and Magnetic Resonance Study. Biological Psychiatry, 2019, 85, 368-378.	1.3	72
20	Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. Neuropsychopharmacology, 2020, 45, 622-631.	5.4	63
21	The effects of psychosocial stress on dopaminergic function and the acute stress response. ELife, 2019, 8, .	6.0	53
22	Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. Journal of Psychopharmacology, 2015, 29, 892-897.	4.0	51
23	The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis. Molecular Psychiatry, 2021, 26, 1310-1320.	7.9	47
24	Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity. Psychopharmacology, 2014, 231, 4323-4335.	3.1	44
25	Magnitude and heterogeneity of brain structural abnormalities in 22q11.2 deletion syndrome: a meta-analysis. Molecular Psychiatry, 2020, 25, 1704-1717.	7.9	39
26	The practical management of refractory schizophrenia - the Maudsley Treatment REview and Assessment Team service approach. Acta Psychiatrica Scandinavica, 2014, 130, 427-438.	4.5	38
27	Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications. Psychopharmacology, 2019, 236, 1985-1997.	3.1	35
28	Individual Differences in Response to Antidepressants. JAMA Psychiatry, 2021, 78, 490.	11.0	26
29	Reappraising the variability of effects of antipsychotic medication in schizophrenia: a metaâ€analysis. World Psychiatry, 2022, 21, 287-294.	10.4	26
30	Chronic psychosocial stressors are associated with alterations in salience processing and corticostriatal connectivity. Schizophrenia Research, 2019, 213, 56-64.	2.0	25
31	Prevalence of treatment-resistant psychoses in the community: A naturalistic study. Journal of Psychopharmacology, 2019, 33, 1248-1253.	4.0	24
32	The relationship between childhood trauma, dopamine release and dexamphetamine-induced positive psychotic symptoms: a [11C]-(+)-PHNO PET study. Translational Psychiatry, 2019, 9, 287.	4.8	23
33	Dopamine and glutamate in individuals at high risk for psychosis: a metaâ€analysis of in vivo imaging findings and their variability compared to controls. World Psychiatry, 2021, 20, 405-416.	10.4	22
34	The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species. Psychopharmacology, 2019, 236, 3257-3270.	3.1	21
35	Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study. Neuropsychopharmacology, 2020, 45, 641-648.	5.4	21
36	Glutamate levels in the anterior cingulate cortex in un-medicated first episode psychosis: a proton magnetic resonance spectroscopy study. Scientific Reports, 2019, 9, 8685.	3.3	17

#	Article	IF	Citations
37	Task-induced functional brain connectivity mediates the relationship between striatal D2/3 receptors and working memory. ELife, 2019, 8, .	6.0	17
38	N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging study. Translational Psychiatry, 2021, 11, 425.	4.8	14
39	Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study. Molecular Psychiatry, 2023, 28, 1995-2006.	7.9	13
40	Dopaminergic organization of striatum is linked to cortical activity and brain expression of genes associated with psychiatric illness. Science Advances, 2021, 7, .	10.3	13
41	Amygdala reactivity in ethnic minorities and its relationship to the social environment: an fMRI study. Psychological Medicine, 2018, 48, 1985-1992.	4.5	12
42	The magnitude and heterogeneity of antidepressant response in depression: A meta-analysis of over 45,000 patients. Journal of Affective Disorders, 2020, 276, 991-1000.	4.1	11
43	The Topography of Striatal Dopamine and Symptoms in Psychosis: An Integrative Positron Emission Tomography and Magnetic Resonance Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 1040-1051.	1.5	11
44	Î²-Adrenoceptor blockade modulates fusiform gyrus activity to black versus white faces. Psychopharmacology, 2015, 232, 2951-2958.	3.1	10
45	Glutamate connectivity associations converge upon the salience network in schizophrenia and healthy controls. Translational Psychiatry, 2021, 11, 322.	4.8	10
46	Glutamatergic function in a genetic high-risk group for psychosis: A proton magnetic resonance spectroscopy study in individuals with 22q11.2 deletion. European Neuropsychopharmacology, 2019, 29, 1333-1342.	0.7	8
47	Dopamine partial agonists and prodopaminergic drugs for schizophrenia: Systematic review and meta-analysis of randomized controlled trials. Neuroscience and Biobehavioral Reviews, 2022, 135, 104568.	6.1	8
48	Cannabis Use Linked to Altered Functional Connectivity of the Visual Attentional Connectivity in Patients With Psychosis and Controls. Schizophrenia Bulletin Open, 2020, 1, .	1.7	7
49	Assessing the impact of different penalty factors of the Bayesian reconstruction algorithm Q.Clear on in vivo low count kinetic analysis of [11C]PHNO brain PET-MR studies. EJNMMI Research, 2022, 12, 11.	2.5	7
50	Examining the variability of neurocognitive functioning in individuals at clinical high risk for psychosis: a meta-analysis. Translational Psychiatry, 2022, 12, 198.	4.8	7
51	Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study. British Journal of Psychiatry, 2022, 221, 740-747.	2.8	6
52	Community treatment orders for patients with psychosis. Lancet, The, 2013, 382, 501.	13.7	5
53	Treatment-Resistant Schizophrenia in a Patient With 17q12 Duplication. Biological Psychiatry, 2016, 80, e19-e20.	1.3	4
54	The Relationship Between Dopamine Synthesis Capacity and Release: Implications for Psychosis. Neuropsychopharmacology, 2018, 43, 1195-1196.	5.4	4

#	Article	IF	Citations
55	Disentangling relapse and adherence in psychosis. Lancet Psychiatry,the, 2020, 7, 722-723.	7.4	4
56	Variability of glucose, insulin, and lipid disturbances in first-episode psychosis: a meta-analysis. Psychological Medicine, 2023, 53, 3150-3156.	4.5	4
57	Reinventing schizophrenia: The rules of the game. Schizophrenia Research, 2022, 242, 94-95.	2.0	3
58	Magnitude and variability of structural brain abnormalities in neuropsychiatric disease: protocol for a network meta-analysis of MRI studies. Evidence-Based Mental Health, 2021, 24, 111-114.	4.5	2
59	Acute psychological impact of coronavirus disease 2019 outbreak among psychiatric professionals in China: a multicentre, cross-sectional, web-based study. BMJ Open, 2021, 11, e047828.	1.9	2
60	The relationship between glutamate, dopamine, and cortical gray matter: A simultaneous PET-MR study. Molecular Psychiatry, 2022, 27, 3493-3500.	7.9	2
61	Letter to the Editor. Journal of Anxiety Disorders, 2013, 27, 543.	3.2	1
62	The effect of ketamine on psychopathology and implications for understanding schizophrenia: a meta-analysis. European Neuropsychopharmacology, 2019, 29, S611.	0.7	1
63	Treatment of First-Episode Schizophrenia in a Young Woman. JAMA Psychiatry, 2020, 77, 211.	11.0	1
64	The diagnosis debate. Lancet Psychiatry,the, 2014, 1, 498.	7.4	0
65	Methodology of the SEYLE trial on suicide prevention in schools. Lancet, The, 2015, 386, 853-854.	13.7	0
66	Ethnicity, the amygdala, and the social environment: a neuroimaging study. Lancet, The, 2017, 389, S67.	13.7	0
67	282. Amygdala Reactivity in Ethnic Minority Individuals, and Its Relationship to the Social Environment. Biological Psychiatry, 2017, 81, S116.	1.3	0
68	F226. The Relationship Between Cortical Glutamate and Striatal Dopamine Function in Psychosis: A Multi-Modal PET and MRS Imaging Study in First Episode Psychosis. Biological Psychiatry, 2018, 83, S326-S327.	1.3	0
69	Mesolimbic dopamine function and salience network connectivity: An integrative PET and MR study. European Neuropsychopharmacology, 2019, 29, S596-S597.	0.7	0
70	Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0	
71	Commissions, coercion and choice. The Psychiatrist, 2013, 37, 179-179.	0.3	0